From the formulary watch journal the FDA warns of joint pain for DPP-4 diabetes drugs ('gliptins) Hopefully, diabetics on one don't need cipro nor have to run a mararthon. However the side effect varied between 1 or 100s of days of onset. They FDA came to this concludion after reciweing case reports in the Adverse Event Reporting System (FAERS) database and the medical literature.
FormularyWatch/Source: FDA
Tuesday, September 8, 2015
Monday, September 7, 2015
The cdc is hosting a webinar and allowing people to submit comments on new prescribing rules. Feel free to look at it.
Happy labor day in the usa.
cdc.gov
Happy labor day in the usa.
cdc.gov
Sunday, September 6, 2015
News one will get in the business mail.
Merck Recalls TEMODAR and Temozolomide Bottles With Cracked Childproof Caps
Merck, in conjunction with Consumer Product Safety Commission, is recalling TEMODAR® and temozolomide bottles with cracks in the child-resistant caps. Merck believes that approximately 1,100 bottles out of an estimated 276,000 distributed bottles of TEMODAR and temozolomide capsules (generic), medicines used to treat adults with certain brain cancer tumors, could potentially have cracked caps. The recall affects the medicine manufactured and distributed by Merck as TEMODAR in addition to the temozolomide capsules manufactured and packaged by Merck but sold and distributed by Sandoz, under the Sandoz label. Merck’s TEMODAR in sachets (or pouches) are not affected.
Merck is asking all patients to inspect all bottles of TEMODAR (temozolomide) capsules and all bottles of temozolomide capsules for cracks in the child-resistant bottle caps. If cracks are found, Merck advises keeping the bottles out of the reach of children. The quality of the medication in the bottles is not affected and patients may continue to use the drug as directed. Instructions for obtaining a replacement cap are provided in the press release on Merck’s website.
Merck Recalls TEMODAR and Temozolomide Bottles With Cracked Childproof Caps
Merck, in conjunction with Consumer Product Safety Commission, is recalling TEMODAR® and temozolomide bottles with cracks in the child-resistant caps. Merck believes that approximately 1,100 bottles out of an estimated 276,000 distributed bottles of TEMODAR and temozolomide capsules (generic), medicines used to treat adults with certain brain cancer tumors, could potentially have cracked caps. The recall affects the medicine manufactured and distributed by Merck as TEMODAR in addition to the temozolomide capsules manufactured and packaged by Merck but sold and distributed by Sandoz, under the Sandoz label. Merck’s TEMODAR in sachets (or pouches) are not affected.
Merck is asking all patients to inspect all bottles of TEMODAR (temozolomide) capsules and all bottles of temozolomide capsules for cracks in the child-resistant bottle caps. If cracks are found, Merck advises keeping the bottles out of the reach of children. The quality of the medication in the bottles is not affected and patients may continue to use the drug as directed. Instructions for obtaining a replacement cap are provided in the press release on Merck’s website.
Saturday, September 5, 2015
Carter, who is 90 years old, said he was "surprisingly at ease" when he received the news that the melanoma previously found in his liver has now been discovered in four spots in his brain. He will begin his first course of treatment later today, he announced in a press conference in Atlanta.
Carter had a small mass removed from his liver earlier this month, and last week he announced that surgery had revealed the cancer. He initially felt ill back in May, during a trip to Guyana.
http://www.washingtonexaminer.com/carter-says-cancer-has-spread-to-his-brain/article/2570534
Carter had a small mass removed from his liver earlier this month, and last week he announced that surgery had revealed the cancer. He initially felt ill back in May, during a trip to Guyana.
http://www.washingtonexaminer.com/carter-says-cancer-has-spread-to-his-brain/article/2570534
Come one come all give your drugs away!
Virginia will participate, Saturday, September 26, 2015 in the tenth National Prescription Drug Take-Back Day. Sponsored by the Drug Enforcement Administration (DEA), this collaborative effort between state and local law enforcement agencies provides residents with an opportunity to dispose of potentially dangerous controlled substances in their medicine cabinets in an environmentally safe manner. Healthcare practitioners are encouraged to advise patients about this service and to remind them it is free and anonymous with no questions asked. Collection activities will take place from 10:00 a.m. through 2:00 p.m. at sites coordinated by law enforcement throughout Virginia. To find a collection site nearby or for more information, click on the following link: http://www.deadiversion.usdoj.
Thursday, September 3, 2015
Wednesday, September 2, 2015
From nabp: ugly weather, ugly decision making process.
Winter is the peak season for full-time college students to start non-medical use of prescription drugs, such as pain relievers and stimulants, indicates a new study by the Substance Abuse and Mental Health Services Administration (SAMHSA). The study, which tracks initiation by month, reveals that in the past year, approximately 251,000 full-time college students started the non-medical use of pain relievers, with an average of 700 initiates a day. However, this rate rises to 850 initiates a day during December, according the study. Further, more students start non-medical use of stimulant medications in November, December, and April. Specifically, about 500 students per day start abusing stimulants during those months, compared with 400 students on an average day. SAMHSA notes that because the rise in the initiation of non-medical use of prescription stimulants coincides with the times of the year that many college final exams and midterm exams occur, this may suggest that students believe non-medical use of stimulants can benefit academic performance.
Winter is the peak season for full-time college students to start non-medical use of prescription drugs, such as pain relievers and stimulants, indicates a new study by the Substance Abuse and Mental Health Services Administration (SAMHSA). The study, which tracks initiation by month, reveals that in the past year, approximately 251,000 full-time college students started the non-medical use of pain relievers, with an average of 700 initiates a day. However, this rate rises to 850 initiates a day during December, according the study. Further, more students start non-medical use of stimulant medications in November, December, and April. Specifically, about 500 students per day start abusing stimulants during those months, compared with 400 students on an average day. SAMHSA notes that because the rise in the initiation of non-medical use of prescription stimulants coincides with the times of the year that many college final exams and midterm exams occur, this may suggest that students believe non-medical use of stimulants can benefit academic performance.
Subscribe to:
Posts (Atom)



